Pfizer (NYSE: PFE) Q2 2026 Earnings Tuesday August 4 Beat Consensus With Revenue of $15 Billion and Adjusted Diluted EPS of $0.77; Full-Year 2026 Revenue Guidance Midpoint Raised to $60.5-62.5 Billion (From $59.5-62.5 Billion) With Approximately $1.5 Billion Upside From Non-COVID Products Partially Offset by a Reduction in COVID Treatment Forecast to Approximately $4 Billion for the Year; CEO Albert Bourla Says the Obesity Program Is Advancing With Substantial Momentum and Adjusted R&D Expenses Increased 12% Operationally to $2.7 Billion Driven by Oncology and Obesity Product Candidates; Shares Rose Approximately 1.86% to $25.50
Pfizer (NYSE: PFE) reported Q2 2026 earnings Tuesday August 4, 2026 with revenue of $15 billion and adjusted diluted EPS of $0.77, beating analyst expectations. The company raised the midpoint of its full-year 2026 revenue guidance to $60.5-62.5 billion, up from a previous $59.5-62.5 billion range. The guidance update reflected approximately $1.5 billion in upside from non-COVID products, partially offset by a reduction in the company's forecast for COVID-19 treatments (Paxlovid and Comirnaty) now pegged at approximately $4 billion for the year. Adjusted R&D expenses increased 12% operationally to $2.7 billion, driven by increased spending on oncology and obesity product candidates. CEO Albert Bourla said in the earnings call that the obesity program is advancing with substantial momentum and that the oncology portfolio remains a source of strength. Shares rose approximately 1.86% to $25.50 following the announcement. Pfizer's obesity program includes danuglipron (oral GLP-1) and multiple next-generation candidates advanced through the Metsera acquisition; the Metsera monthly-injectable ultra-long-acting GLP-1 candidate produced up to 11% weight loss over 28 weeks in Phase 2b data reported earlier in 2026.